Tags: pfizer | biontech | omicron | fda | covid vaccine

Pfizer Asks FDA to Authorize Omicron Vaccine

Pfizer Asks FDA to Authorize Omicron Vaccine
(AP)

Monday, 22 August 2022 10:54 AM EDT

Pfizer Inc and partner BioNTech said on Monday they had completed a submission to the U.S. Food and Drug Administration for authorization of a COVID-19 vaccine adapted to target the omicron variant.

The request was for a so-called bivalent vaccine that contains the dominant BA.4/BA.5 variants of the virus, along with the original coronavirus strain.

The FDA in June asked COVID-19 vaccine makers to tailor shots to target the two subvariants.

The U.S. government has since signed a deal with both Moderna and Pfizer for delivery of omicron-adapted vaccines, pending clearance.

© 2025 Thomson/Reuters. All rights reserved.


StreetTalk
Pfizer Inc and partner BioNTech said on Monday they had completed a submission to the U.S. Food and Drug Administration for authorization of a COVID-19 vaccine adapted to target the omicron variant.
pfizer, biontech, omicron, fda, covid vaccine
91
2022-54-22
Monday, 22 August 2022 10:54 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Newsmax2 Live
 
On Now:2:00a ET • 13 Seconds: Kent State Shooting
Coming Up:3:00a ET • Clint Eastwood: Steel Gaze
Get Newsmax Text Alerts

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© 2025 Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved